Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 336 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 14 words
    • Study description expanded, about 13 words
  2. 18 versions Re-verified since Sep 10, 2025, no change to tracked fieldsv318-v335
  3. Study Status, Study Description, Eligibilityv317
  4. 30 versions Re-verified since Jun 27, 2024, no change to tracked fieldsv287-v316
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.
Trial Details
NCT Number NCT00001238
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Familial Renal Cancer (FRC), Clear Cell Renal Cancer
Related terms Carcinoma, Renal Cell, Hereditary leiomyomatosis and renal cell cancer, Kidney Neoplasms, Pheochromocytoma
Enrollment 5,000 participants
Start Date
Updated on ClinicalTrials.gov